| Autor: |
KASER, A., NOVICK, D., RUBINSTEIN, M., SIEGMUND, B., ENRICH, B., KOCH, R. O., VOGEL, W., KIM, S. H., DINARELLO, C. A., TILG, H. |
| Předmět: |
|
| Zdroj: |
Clinical & Experimental Immunology; Aug2002, Vol. 129 Issue 2, p332-338, 7p |
| Abstrakt: |
SUMMARY Interleukin-18 (IL-18), derived from macrophages and Kupffer cells, is the central pro-inflammatory cytokine leading to experimental liver failure. IL-18 binding protein (IL-18BP) is a circulating protein that binds IL-18 and neutralizes its activity. Since IL-18 production is increased in chronic HCV infection, we asked whether IFN-α might act on the IL-18/IL-18BP system in HCV patients. IL-18BP, total and free IL-18 plasma levels were determined in 13 HCV patients receiving 1 × 107 IU IFN-α subcutaneously daily for 28 days. The in vitro effects of IFN-α on macrophage IL-18BP and IL-18 were studied by enzyme-linked immunosorbent assays and Northern analysis. IFN-α administration increased IL-18BP plasma levels 3·24 fold 24 h after institution of therapy, resulting in a 67·4% reduction of free IL-18. Total IL-18 levels decreased from day +24 on. In vitro , IFN-α diminished IL-18 release from macrophages of healthy volunteers and chronic HCV patients. On top of its inhibitory effects on IL-1 and TNF-α release, IFN-α also exerts its anti-inflammatory action in vivo by induction of IL-18BP. These anti-inflammatory properties might account – together with its antiviral action – for its clinical efficacy in chronic hepatitis C. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
